Nick van Dijk

1.0k total citations
16 papers, 273 citations indexed

About

Nick van Dijk is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nick van Dijk has authored 16 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 14 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nick van Dijk's work include Cancer Immunotherapy and Biomarkers (14 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Urinary and Genital Oncology Studies (8 papers). Nick van Dijk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Urinary and Genital Oncology Studies (8 papers). Nick van Dijk collaborates with scholars based in Netherlands, Germany and Switzerland. Nick van Dijk's co-authors include Michiel S. van der Heijden, Christian U. Blank, Jonathan E. Rosenberg, Samuel A. Funt, Thomas Powles, Akhila Wimalasingham, Bernadett Szabados, Simon Hughes, Thomas Powles and Simon Chowdhury and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Nick van Dijk

15 papers receiving 273 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nick van Dijk Netherlands 8 180 151 72 65 52 16 273
Victoria Hinder New Zealand 7 109 0.6× 136 0.9× 64 0.9× 42 0.6× 67 1.3× 18 264
J L Lee South Korea 4 235 1.3× 231 1.5× 82 1.1× 27 0.4× 34 0.7× 6 353
Nuno Vau Portugal 7 128 0.7× 163 1.1× 79 1.1× 43 0.7× 93 1.8× 13 267
Maria Lucia Iacovino Italy 6 134 0.7× 56 0.4× 72 1.0× 31 0.5× 56 1.1× 13 232
Amita Mistry United States 4 214 1.2× 44 0.3× 108 1.5× 55 0.8× 20 0.4× 8 245
Daniel D. Kirchoff United States 12 218 1.2× 71 0.5× 99 1.4× 43 0.7× 83 1.6× 22 304
Daiyuan Ma China 10 139 0.8× 60 0.4× 110 1.5× 65 1.0× 77 1.5× 40 274
Juan Francisco Rodríguez-Moreno Spain 9 86 0.5× 59 0.4× 71 1.0× 20 0.3× 74 1.4× 37 192
Benjamin Miron United States 8 130 0.7× 131 0.9× 160 2.2× 11 0.2× 81 1.6× 23 277
Michele Sisani Italy 7 49 0.3× 82 0.5× 68 0.9× 22 0.3× 40 0.8× 20 176

Countries citing papers authored by Nick van Dijk

Since Specialization
Citations

This map shows the geographic impact of Nick van Dijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick van Dijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick van Dijk more than expected).

Fields of papers citing papers by Nick van Dijk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick van Dijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick van Dijk. The network helps show where Nick van Dijk may publish in the future.

Co-authorship network of co-authors of Nick van Dijk

This figure shows the co-authorship network connecting the top 25 collaborators of Nick van Dijk. A scholar is included among the top collaborators of Nick van Dijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick van Dijk. Nick van Dijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Dijk, Nick van, Daniël J. Vis, Bram van den Broek, et al.. (2025). Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial. European Journal of Cancer. 229. 115731–115731.
2.
Gil-Jimenez, Alberto, Nick van Dijk, Joris L. Vos, et al.. (2024). Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors. Nature Communications. 15(1). 2538–2538. 10 indexed citations
3.
Dijk, Nick van, Maurits L. van Montfoort, Iris M. Seignette, et al.. (2024). Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update.. Journal of Clinical Oncology. 42(16_suppl). 4593–4593. 1 indexed citations
4.
Cheng, Phil F., et al.. (2022). Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. Frontiers in Immunology. 12. 793992–793992. 21 indexed citations
5.
Dijk, Nick van, Jeantine M. de Feijter, Maurits L. van Montfoort, et al.. (2022). Survival after neoadjuvant/induction combination immunotherapy vs combination platinum‐based chemotherapy for locally advanced (Stage III) urothelial cancer. International Journal of Cancer. 151(11). 2004–2011. 9 indexed citations
6.
Montfoort, Maurits L. van, Nick van Dijk, Ingrid Hofland, et al.. (2021). A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. Clinical Genitourinary Cancer. 20(2). e173–e179. 1 indexed citations
7.
Trebeschi, Stefano, Zuhir Bodalal, Nick van Dijk, et al.. (2021). Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy. Frontiers in Oncology. 11. 637804–637804. 9 indexed citations
8.
Dijk, Nick van, Alberto Gil-Jimenez, Karīna Siliņa, et al.. (2021). The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. Frontiers in Immunology. 12. 793964–793964. 28 indexed citations
9.
Suelmann, Britt B.M., Nick van Dijk, Kees Hendricksen, et al.. (2021). LBA31 High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2). Annals of Oncology. 32. S1305–S1306. 5 indexed citations
10.
Dijk, Nick van, Karīna Siliņa, Kees Hendricksen, et al.. (2020). Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).. Journal of Clinical Oncology. 38(15_suppl). 5020–5020. 5 indexed citations
11.
Heijden, Michiel S. van der, Nick van Dijk, Laura A. Smit, et al.. (2019). Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO). Annals of Oncology. 30. v358–v358. 19 indexed citations
12.
Dijk, Nick van, Samuel A. Funt, Christian U. Blank, et al.. (2018). The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology. 75(3). 435–444. 91 indexed citations
13.
Dijk, Nick van, Pia Kvistborg, Ton N. Schumacher, et al.. (2018). Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO). Annals of Oncology. 29. viii329–viii329. 1 indexed citations
14.
Liaño, Alfonso Gómez de, Andrea Necchi, Pernelle Lavaud, et al.. (2017). Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective. Annals of Oncology. 28. v303–v303. 2 indexed citations
15.
Szabados, Bernadett, Nick van Dijk, Yen Zhi Tang, et al.. (2017). Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology. 73(2). 149–152. 70 indexed citations
16.
Reißner, Regine, et al.. (2017). QualyGridS - Standardized qualifying tests of electrolysers for grid services. elib (German Aerospace Center). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victoria Hinder Breakdown of academic impact, for papers by J L Lee Breakdown of academic impact, for papers by Nuno Vau Breakdown of academic impact, for papers by Maria Lucia Iacovino Breakdown of academic impact, for papers by Amita Mistry Breakdown of academic impact, for papers by Daniel D. Kirchoff Breakdown of academic impact, for papers by Daiyuan Ma Breakdown of academic impact, for papers by Juan Francisco Rodríguez-Moreno Breakdown of academic impact, for papers by Benjamin Miron Breakdown of academic impact, for papers by Michele Sisani
Rankless by CCL
2026